Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Levels of depression and anxiety are higher in people with severe rheumatoid arthritis

Levels of depression and anxiety in people with severe rheumatoid arthritis are higher than previously reported, according to new research. As a result of their findings, a multi-centre team led by researchers at the Arthritis Research UK Centre for Genetics and Genomics at the University of Manchester, say that patients with severe active disease, who are waiting to go onto a biological therapy, should be routinely screened for depression by their doctors.

From The University of Manchester 21 Jan 2014

Gene therapies correct three forms of retinal degenerative diseases

Gene therapies developed by University of Pennsylvania School of Veterinary Medicine researchers have worked to correct different forms of blindness. While effective, the downside to these approaches to vision rescue is that each disease requires its own form of gene therapy to correct the particular genetic mutation involved, a time consuming and complex process.

17 Jan 2014

Discovery opens new therapeutic avenue for chronic skin condition affecting millions

Researchers from the La Jolla Institute for Allergy and Immunology have revealed a critical player in the cellular interactions leading to eczema - a chronic inflammatory skin condition affecting more than 14 million U.S. children and adults.

10 Jan 2014

TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn's disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life.

9 Jan 2014

Nociceptin in brain naturally moderates effects of stress

Collaborating scientists at The Scripps Research Institute (TSRI), the National Institutes of Health (NIH) and the University of Camerino in Italy have published new findings on a system in the brain that naturally moderates the effects of stress.

8 Jan 2014

Plasma thermogram can serve as an indicator of cervical cancer

Researchers at the University of Louisville have confirmed that using the heat profile from a person's blood, called a plasma thermogram, can serve as an indicator for the presence or absence of cervical cancer, including the stage of cancer.

8 Jan 2014

Longer duration breastfeeding may reduce risk of rheumatoid arthritis

In a new study of over 7,000 older Chinese women published online today in the journal Rheumatology, breastfeeding - especially for a longer duration - is shown to be associated with a lower risk of rheumatoid arthritis.

6 Jan 2014

Biologists discover effective strategy that could prevent immune system from rejecting grafts

Biologists at UC San Diego have discovered an effective strategy that could prevent the human immune system from rejecting the grafts derived from human embryonic stem cells, a major problem now limiting the development of human stem cell therapies.

3 Jan 2014

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

CEL-SCI Corporation, a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 5,238,095 shares of common stock and warrants to purchase an aggregate of 5,238,095 shares of common stock. The

27 Dec 2013

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cells-macrophages-are stimulated in response to pathogens.

27 Dec 2013

Genetics of rheumatoid arthritis contributes to biology and drug discovery

The results of the largest international study to date into the genetic basis of rheumatoid arthritis shed light on the biology of the disease and provide evidence that large-scale genetic studies can assist in the identification of new drugs for complex disorders such as rheumatoid arthritis.

26 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

Death rates two times higher in postmenopausal women with anti-CCP and RA antibodies

New research shows mortality rates are two times higher in postmenopausal women with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Findings published in the American College of Rheumatology (ACR) journal Arthritis & Rheumatism, soon to be called Arthritis & Rheumatology, indicate the higher mortality rates persisted after adjusting for age, positive rheumatoid factor, positive antinuclear antibodies (ANA) and disease modifying anti-rheumatic drug (DMARD) use.

23 Dec 2013

Six common diseases arise from DNA changes, finds new research

Many rare disorders are caused by gene mutation, like sickle cell anemia. Yet until now the underlying genetic cause of more common conditions - for example, rheumatoid arthritis - has evaded scientists for years.

22 Dec 2013

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability.

20 Dec 2013

Hispanic mortality paradox found in RA patients

The so-called “Hispanic survival paradox” has been found to extend to patients with rheumatoid arthritis, whereby Hispanic people with the condition tend have more severe symptoms but equivalent mortality to non-Hispanic White individuals.

19 Dec 2013

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.

19 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Levels of depression and anxiety are higher in people with severe rheumatoid arthritis

Gene therapies correct three forms of retinal degenerative diseases

Discovery opens new therapeutic avenue for chronic skin condition affecting millions

TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

Nociceptin in brain naturally moderates effects of stress

Plasma thermogram can serve as an indicator of cervical cancer

Longer duration breastfeeding may reduce risk of rheumatoid arthritis

Biologists discover effective strategy that could prevent immune system from rejecting grafts

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Genetics of rheumatoid arthritis contributes to biology and drug discovery

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Death rates two times higher in postmenopausal women with anti-CCP and RA antibodies

Six common diseases arise from DNA changes, finds new research

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Hispanic mortality paradox found in RA patients

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in